{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T11:15:39Z","timestamp":1763810139607,"version":"3.37.3"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T00:00:00Z","timestamp":1571961600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T00:00:00Z","timestamp":1571961600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Information on subgroup assessments in systematic reviews (SR) of atrial fibrillation (AF) is limited. This review aims to describe subgroup analyses in AF SRs to inform the design of SRs and randomized trials as well as clinical practice.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a cross sectional meta-epidemiological study of Cochrane AF reviews by searching AF (including variants) in the title, abstract, or keyword field without date or language restrictions (Issue 9; September 2018). Two reviewers independently extracted study characteristics to summarize frequency of subgroups pre-specified and conducted and report credibility of subgroup effects claimed.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 39 Cochrane reviews identified, 17 met inclusion criteria (including 168 reports of 127 randomized trials) and the majority (16; 94.1%) conducted meta-analysis of outcomes. Most (13; 76.5%) planned pre-specified subgroup analyses; 7 of which (41.2%) conducted subgroups. In these 7 reviews, 56 subgroups were planned, 17 (30.4%) conducted and 6 (10.7%) yielded subgroup effects. Variables such as co-morbid disease, stroke risk factors, prior stroke\/transient ischemic attack, age, race, and sex represented 44% (24 subgroups) of all planned subgroups (8 conducted; 14.3%); however, information on covariate selection was lacking. Overall, more subgroups were planned than conducted (mean difference (95% CI) 2.3 (1.2\u20133.5, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001)). Of all subgroups conducted, anticoagulant characteristics comprised a third of all subgroup effects (<jats:italic>n<\/jats:italic>\u2009=\u20095, 35.7%).<\/jats:p>\n                <jats:p>The credibility of subgroups identified (<jats:italic>n<\/jats:italic>\u2009=\u200914) was assessed and less than half (43%) represented one of a small number of pre-specified hypothesis and rarely were effects seen within studies (7%). Of 5 reviews that reported subgroup effects, only 3 discussed subgroup effects as part of the overall conclusions; none discussed credibility of subgroup effects.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This meta-epidemiological review of a subset of Cochrane AF reviews suggests that planning and reporting of subgroup analyses in AF reviews can be improved to better inform clinical management. Most pre-specified subgroup analyses were not performed, important variables (such as stroke, bleeding risk, and other comorbidities) were rarely examined and credibility of subgroup effects claimed was low. Future reviews should aim to identify important subgroups in their protocols and use recommended approaches to test subgroup effects in order to better support clinical decision-making.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13643-019-1152-z","type":"journal-article","created":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T17:32:03Z","timestamp":1572024723000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["A meta-epidemiological study of subgroup analyses in cochrane systematic reviews of atrial fibrillation"],"prefix":"10.1186","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1239-3265","authenticated-orcid":false,"given":"Miney","family":"Paquette","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahlam Mohammed","family":"Alotaibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robby","family":"Nieuwlaat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Santesso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Mbuagbaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,25]]},"reference":[{"issue":"7023","key":"1152_CR1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/bmj.312.7023.71","volume":"312","author":"DL Sackett","year":"1996","unstructured":"Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn\u2019t. BMJ. 1996;312(7023):71\u20132.","journal-title":"BMJ"},{"unstructured":"Deeks JJ HJ, Altman DJ (editors). Chapter 9: Analysing data and undertaking meta-analyses. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from \n                    www.handbook.cochrane.org\n                    \n                  . 2011.","key":"1152_CR2"},{"key":"1152_CR3","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/1471-2288-13-106","volume":"13","author":"JJ Gagnier","year":"2013","unstructured":"Gagnier JJ, Morgenstern H, Altman DG, Berlin J, Chang S, McCulloch P, et al. Consensus-based recommendations for investigating clinical heterogeneity in systematic reviews. BMC Med Res Methodol. 2013;13:106.","journal-title":"BMC Med Res Methodol"},{"key":"1152_CR4","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/1471-2288-12-111","volume":"12","author":"JJ Gagnier","year":"2012","unstructured":"Gagnier JJ, Moher D, Boon H, Beyene J, Bombardier C. Investigating clinical heterogeneity in systematic reviews: a methodologic review of guidance in the literature. BMC Med Res Methodol. 2012;12:111.","journal-title":"BMC Med Res Methodol"},{"issue":"11","key":"1152_CR5","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539\u201358.","journal-title":"Stat Med"},{"issue":"12","key":"1152_CR6","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.jclinepi.2011.03.017","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 7. Rating the quality of evidence--inconsistency. J Clin Epidemiol. 2011;64(12):1294\u2013302.","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"1152_CR7","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1002\/sim.1187","volume":"21","author":"SG Thompson","year":"2002","unstructured":"Thompson SG, Higgins JPT. How should meta-regression analyses be undertaken and interpreted? Stat Med. 2002;21(11):1559\u201373.","journal-title":"Stat Med"},{"issue":"1","key":"1152_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1258\/1355819021927674","volume":"7","author":"J Higgins","year":"2002","unstructured":"Higgins J, Thompson S, Deeks J, Altman D. Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice. J Health Serv Res Policy. 2002;7(1):51\u201361.","journal-title":"J Health Serv Res Policy"},{"issue":"7650","key":"1152_CR9","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u20136.","journal-title":"BMJ"},{"issue":"4","key":"1152_CR10","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1001\/jama.2013.285063","volume":"311","author":"Xin Sun","year":"2014","unstructured":"Sun X, Ioannidis JP, Agoritsas T, Alba AC, Guyatt G. How to use a subgroup analysis: users\u2019 guide to the medical literature. JAMA 2014;311(4):405-411.","journal-title":"JAMA"},{"key":"1152_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jclinepi.2017.11.022","volume":"95","author":"MJ Page","year":"2018","unstructured":"Page MJ, Altman DG, McKenzie JE, Shamseer L, Ahmadzai N, Wolfe D, et al. Flaws in the application and interpretation of statistical analyses in systematic reviews of therapeutic interventions were common: a cross-sectional analysis. J Clini Epidemiol. 2018;95:7\u201318.","journal-title":"J Clini Epidemiol"},{"issue":"6","key":"1152_CR12","doi-asserted-by":"publisher","first-page":"e0128804","DOI":"10.1371\/journal.pone.0128804","volume":"10","author":"S Donegan","year":"2015","unstructured":"Donegan S, Williams L, Dias S, Tudur-Smith C, Welton N. Exploring treatment by covariate interactions using subgroup analysis and meta-regression in cochrane reviews: a review of recent practice. PLoS ONE. 2015;10(6):e0128804.","journal-title":"PLoS ONE"},{"issue":"6","key":"1152_CR13","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.jclinepi.2010.08.002","volume":"64","author":"RD Riley","year":"2011","unstructured":"Riley RD, Gates S, Neilson J, Alfirevic Z. Statistical methods can be improved within Cochrane pregnancy and childbirth reviews. J Clin Epidemiol. 2011;64(6):608\u201318.","journal-title":"J Clin Epidemiol"},{"issue":"22","key":"1152_CR14","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1093\/eurheartj\/ehi505","volume":"26","author":"R Nieuwlaat","year":"2005","unstructured":"Nieuwlaat R, Capucci A, Camm AJ, Olsson SB, Andresen D, Davies DW, et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2005;26(22):2422\u201334.","journal-title":"Eur Heart J"},{"issue":"6","key":"1152_CR15","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1161\/01.STR.30.6.1223","volume":"30","author":"RG Hart","year":"1999","unstructured":"Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke. 1999;30(6):1223\u20139.","journal-title":"Stroke"},{"issue":"2","key":"1152_CR16","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1378\/chest.09-1584","volume":"137","author":"GY Lip","year":"2010","unstructured":"Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010;137(2):263\u201372.","journal-title":"Chest"},{"issue":"8","key":"1152_CR17","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","volume":"22","author":"PA Wolf","year":"1991","unstructured":"Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983\u20138.","journal-title":"Stroke"},{"issue":"11","key":"1152_CR18","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.jacc.2010.05.028","volume":"56","author":"R Marinigh","year":"2010","unstructured":"Marinigh R, Lip GY, Fiotti N, Giansante C, Lane DA. Age as a risk factor for stroke in atrial fibrillation patients: implications for thromboprophylaxis. J Am Coll Cardiol. 2010;56(11):827\u201337.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"1152_CR19","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.clinthera.2014.07.015","volume":"36","author":"M Agarwal","year":"2014","unstructured":"Agarwal M, Apostolakis S, Lane DA, Lip GY. The impact of heart failure and left ventricular dysfunction in predicting stroke, thromboembolism, and mortality in atrial fibrillation patients: a systematic review. Clin Ther. 2014;36(9):1135\u201344.","journal-title":"Clin Ther"},{"issue":"5","key":"1152_CR20","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1161\/CIRCEP.112.972869","volume":"5","author":"GY Lip","year":"2012","unstructured":"Lip GY, Banerjee A, Lagrenade I, Lane DA, Taillandier S, Fauchier L. Assessing the risk of bleeding in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation project. Circ Arrhythm Electrophysiol. 2012;5(5):941\u20138.","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"1152_CR21","doi-asserted-by":"publisher","first-page":"j4008","DOI":"10.1136\/bmj.j4008","volume":"358","author":"BJ Shea","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008.","journal-title":"BMJ"},{"issue":"4","key":"1152_CR22","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1136\/ebmed-2017-110713","volume":"22","author":"MH Murad","year":"2017","unstructured":"Murad MH, Wang Z. Guidelines for reporting meta-epidemiological methodology research. Evid Based Med. 2017;22(4):139\u201342.","journal-title":"Evid Based Med"},{"key":"1152_CR23","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/2046-4053-2-4","volume":"2","author":"A Booth","year":"2013","unstructured":"Booth A, Clarke M, Dooley G, Ghersi D, Moher D, Petticrew M, et al. PROSPERO at one year: an evaluation of its utility. Syst Rev. 2013;2:4.","journal-title":"Syst Rev"},{"doi-asserted-by":"crossref","unstructured":"Aguilar MI, Hart R. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2005;3.","key":"1152_CR24","DOI":"10.1002\/14651858.CD001927.pub2"},{"doi-asserted-by":"crossref","unstructured":"Aguilar MI, Hart R. Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2005;4.","key":"1152_CR25","DOI":"10.1002\/14651858.CD001925.pub2"},{"doi-asserted-by":"crossref","unstructured":"Aguilar MI, Hart R, Pearce LA. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2007;3.","key":"1152_CR26","DOI":"10.1002\/14651858.CD006186.pub2"},{"doi-asserted-by":"crossref","unstructured":"Saxena R, Koudstaal PJ. Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischaemic attack. Cochrane Database Syst Rev. 2004;2.","key":"1152_CR27","DOI":"10.1002\/14651858.CD000185.pub2"},{"doi-asserted-by":"crossref","unstructured":"Saxena R, Koudstaal PJ. Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack. Cochrane Database Syst Rev. 2004;4.","key":"1152_CR28","DOI":"10.1002\/14651858.CD000187.pub2"},{"doi-asserted-by":"crossref","unstructured":"Kimachi M, Furukawa TA, Kimachi K, Goto Y, Fukuma S, Fukuhara S. Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease. Cochrane Database Syst Rev. 2017;(11).","key":"1152_CR29","DOI":"10.1002\/14651858.CD011373.pub2"},{"doi-asserted-by":"crossref","unstructured":"Lafuente-Lafuente C, Valembois L, Bergmann JF, Belmin J. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2015;(3).","key":"1152_CR30","DOI":"10.1002\/14651858.CD005049.pub4"},{"doi-asserted-by":"crossref","unstructured":"Salazar CA, del Aguila D, Cordova EG. Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation. Cochrane Database Syst Rev 2014(3).","key":"1152_CR31","DOI":"10.1002\/14651858.CD009893.pub2"},{"doi-asserted-by":"crossref","unstructured":"Nyong J, Amit G, Adler AJ, Owolabi OO, Perel P, Prieto-Merino D, et al. Efficacy and safety of ablation for people with non-paroxysmal atrial fibrillation. Cochrane Database Syst Rev. 2016;(11).","key":"1152_CR32","DOI":"10.1002\/14651858.CD012088.pub2"},{"doi-asserted-by":"crossref","unstructured":"Huffman MD, Karmali KN, Berendsen MA, Andrei AC, Kruse J, McCarthy PM, et al. Concomitant atrial fibrillation surgery for people undergoing cardiac surgery. Cochrane Database Syst Rev. 2016;(8).","key":"1152_CR33","DOI":"10.1002\/14651858.CD011814.pub2"},{"doi-asserted-by":"crossref","unstructured":"Risom SS, Zwisler AD, Johansen PP, Sibilitz KL, Lindschou J, Gluud C, et al. Exercise-based cardiac rehabilitation for adults with atrial fibrillation. Cochrane Database Syst Rev. 2017;(2).","key":"1152_CR34","DOI":"10.1002\/14651858.CD011197.pub2"},{"doi-asserted-by":"crossref","unstructured":"Bruins Slot KMH, Berge E. Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation. Cochrane Database Syst Rev. 2018;(3).","key":"1152_CR35","DOI":"10.1002\/14651858.CD008980.pub3"},{"doi-asserted-by":"crossref","unstructured":"Clarkesmith DE, Pattison HM, Khaing PH, Lane DA. Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation. Cochrane Database Syst Rev. 2017;(4).","key":"1152_CR36","DOI":"10.1002\/14651858.CD008600.pub3"},{"doi-asserted-by":"crossref","unstructured":"Chen HS, Wen JM, Wu SN, Liu JP. Catheter ablation for paroxysmal and persistent atrial fibrillation. Cochrane Database Syst Rev. (2012, 4).","key":"1152_CR37","DOI":"10.1002\/14651858.CD007101.pub2"},{"doi-asserted-by":"crossref","unstructured":"Heneghan CJ, Garcia-Alamino JM, Spencer EA, Ward AM, Perera R, Bankhead C, et al. Self-monitoring and self-management of oral anticoagulation. Cochrane Database Syst Rev. 2016;(7).","key":"1152_CR38","DOI":"10.1002\/14651858.CD003839.pub3"},{"doi-asserted-by":"crossref","unstructured":"Moran PS, Teljeur C, Ryan M, Smith SM. Systematic screening for the detection of atrial fibrillation. Cochrane Database Syst Rev. 2016;(6).","key":"1152_CR39","DOI":"10.1002\/14651858.CD009586.pub3"},{"doi-asserted-by":"crossref","unstructured":"Mead GE, Elder A, Flapan AD, Cordina J. Electrical cardioversion for atrial fibrillation and flutter. Cochrane Database Syst Rev. 2017;(11).","key":"1152_CR40","DOI":"10.1002\/14651858.CD002903.pub3"},{"doi-asserted-by":"crossref","unstructured":"Bahiru E, de Cates AN, Farr MRB, Jarvis MC, Palla M, Rees K, et al. Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases. Cochrane Database Syst Rev. 2017;(3).","key":"1152_CR41","DOI":"10.1002\/14651858.CD009868.pub3"},{"issue":"22","key":"1152_CR42","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","volume":"285","author":"BF Gage","year":"2001","unstructured":"Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864\u201370.","journal-title":"JAMA"},{"issue":"oct18 2","key":"1152_CR43","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"J. P. T. Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 343:d5928.","journal-title":"BMJ"},{"key":"1152_CR44","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jclinepi.2018.08.007","volume":"104","author":"L Mbuagbaw","year":"2018","unstructured":"Mbuagbaw L, Morgano GP, Lawson DO, Nyambi A, Youssef M, Olaiya O, et al. Subgroup analyses are seldom possible and subgroup effects are rare in Cochrane HIV systematic reviews. J Clin Epidemiol. 2018;104:143\u20134.","journal-title":"J Clin Epidemiol"},{"issue":"mar15 1","key":"1152_CR45","doi-asserted-by":"publisher","first-page":"e2022","DOI":"10.1136\/bmj.e2022","volume":"344","author":"A. D. Oxman","year":"2012","unstructured":"Oxman AD. Subgroup analyses: the devil is in the interpretation. BMJ (Online) 2012;344 (7852) (no pagination) (e2022).","journal-title":"BMJ"},{"issue":"16","key":"1152_CR46","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1001\/archinternmed.2009.250","volume":"169","author":"RHH Groenwold","year":"2009","unstructured":"Groenwold RHH, Donders ART, Van Der Heijden GJMG, Hoes AW, Rovers MM. Confounding of subgroup analyses in randomized data. Arch Intern Med. 2009;169(16):1532\u20134.","journal-title":"Arch Intern Med"},{"unstructured":"Higgins JPT SJ, Savovi\u0107 J, Page MJ, Hr\u00f3bjartsson A, Boutron I RB, Eldridge S. A revised tool for assessing risk of bias in randomized trials In: Chandler J, McKenzie J, Boutron I, Welch V (editors). Cochrane Database Syst Rev 2016, Issue 10 (Suppl1) 2016.","key":"1152_CR47"},{"issue":"5","key":"1152_CR48","doi-asserted-by":"publisher","first-page":"e1002028","DOI":"10.1371\/journal.pmed.1002028","volume":"13","author":"MJ Page","year":"2016","unstructured":"Page MJ, Shamseer L, Altman DG, Tetzlaff J, Sampson M, Tricco AC, et al. Epidemiology and reporting characteristics of systematic reviews of biomedical research: a cross-sectional study. PLoS Med. 2016;13(5):e1002028.","journal-title":"PLoS Med"}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-019-1152-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13643-019-1152-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-019-1152-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T23:19:01Z","timestamp":1603495141000},"score":1,"resource":{"primary":{"URL":"https:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/10.1186\/s13643-019-1152-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,25]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1152"],"URL":"https:\/\/doi.org\/10.1186\/s13643-019-1152-z","relation":{},"ISSN":["2046-4053"],"issn-type":[{"type":"electronic","value":"2046-4053"}],"subject":[],"published":{"date-parts":[[2019,10,25]]},"assertion":[{"value":"20 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval was not required for this study as only aggregate published data were used.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MP is an employee of Boehringer Ingelheim Ltd. The other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"241"}}